Investment publication Seeking Alpha, reports that Bristol-Myers Squibb’s Opdivo (nivolumab) failed to meet primary end point. The American-based global pharmaceutical company was evaluating Opdivo vs. standard of care (topotecan or amrubicin) in patients with relapsed small cell lung cancer. See the article for more details.

Source: Seeking Alpha

Pin It on Pinterest